Author/Authors :
Hyun-Jae Kang، نويسنده , , Hyo-Soo Kim، نويسنده , , Shu-Ying Zhang، نويسنده , , Kyung-Woo Park، نويسنده , , Hyun-Jai Cho، نويسنده , , Bon-Kwon Koo، نويسنده , , Yong-Jin Kim، نويسنده , , Dong Soo Lee، نويسنده , , Dae-Won Sohn، نويسنده , , Kyou-Sup Han، نويسنده , , Byung-Hee Oh، نويسنده , , Myoung-Mook Lee، نويسنده , , Young-Bae Park، نويسنده ,
Abstract :
Background
Bone-marrow stem-cell transplantation has been shown to improve cardiac function in patients with myocardial infarction. We examined the feasibility and efficacy of granulocyte-colony stimulating factor (G-CSF) therapy and subsequent intracoronary infusion of collected peripheral blood stem-cells (PBSCs) in such patients.
Methods
We prospectively randomised 27 patients with myocardial infarction who underwent coronary stenting for the culprit lesion of infarction into three groups; cell infusion (n=10), G-CSF alone (n=10), and control group (n=7). Changes in left ventricular systolic function and perfusion were assessed after 6 months. By December, 2003, seven patients from the cell infusion group, three from the G-CSF group, and one from the control group had been assessed.
Findings
G-CSF injection and intracoronary infusion of the mobilised PBSC did not aggravate inflammation and ischaemia during the periprocedural period. Exercise capacity (mean treadmill exercise time: 450 s [SD 178] at baseline vs 578 s [168] at 6 monthsʹ follow-up, p=0•004), myocardial perfusion (perfusion defect 11•6% [9•6] vs 5•3% [5•0], p=0•020) and systolic function (left ventricular ejection fraction 48•7% [8•3] vs 55•1% [7•4], p=0•005) improved significantly in patients who received cell infusion. However, we noted an unexpectedly high rate of in-stent restenosis at culprit lesion in patients who received G-CSF, and therefore we stopped enrolment.
Interpretation
G-CSF therapy with intracoronary infusion of PBSC showed improved cardiac function, and promoted angiogenesis in patients with myocardial infarction. However, aggravation of restenosis could be a serious problem. In future studies with G-CSF based stem-cell therapy, patients should be carefully monitored for unexpected effects.
Published online March 2, 2004 http://image.thelancet.com/extras/04art1325web.pdf